Price T Rowe Associates Inc C4 Therapeutics, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CCCC
# of Institutions
126Shares Held
53.8MCall Options Held
331KPut Options Held
145K-
Ra Capital Management, L.P. Boston, MA4.88MShares$29.1 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$28.9 Million0.12% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$27.2 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT4.05MShares$24.2 Million1.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.56MShares$21.2 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $292M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...